IL17A and hepatocellular carcinoma: In HCC patients, TAMs, interacting with IL-17-producing cells, have been found to promote tumor proliferation, and CD163-positive TAMs play a suppressive role in the antitumor immune response, which may impact the recurrence of HCC [59,60].